Artículos científicos
Patritumab Deruxtecan in Untreated Hormone Receptor–Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study
Autores: M. Oliveira, C. Falato, J.M. Cejalvo, M. Margelí Vila, P. Tolosa, F.J. Salvador-Bofill, J. Cruz, M. Arumi, A.M. Luna
, J.A. Guerra, M. Vidal, O. Martínez-Sáez, L. Paré, B. González-Farré, E. Sanfeliu, E. Ciruelos, M. Espinosa-Bravo, S. Pernas, Y. Izarzugaza
S. Esker, P.-D. Fan, P. Parul, A. Santhanagopal, D. Sellami, G. Villacampa, J.M. Ferrero-Cafiero, T. Pascual, A. Prat
Abstract: Patritumab deruxtecan (HER3-DXd) is a HER3–directed antibody-drug conjugate composed of a fully human anti-HER3 monoclonal antibody (patritumab) covalently linked to a topoisomerase I inhibitor payload via a stable, tumor-selective, tetrapeptide-based cleavable linker. TOT-HER3 is a window-of-opportunity study designed to assess the biological activity, measured by CelTIL score [ = −.8 × tumor cellularity (in %) + 1.3 × TILs (in %)], and clinical activity of HER3-DXd during short-term (21 days) pre-operative treatment in patients with primary operable HER2-negative early breast cancer.
Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment
Autores: Christian Siso, Antonio Esgueva, Joaquin Rivero, Clara Morales, Ignacio Miranda, Vicente Peg, Antonio Gil-Moreno, Martin Espinosa-Bravo, Isabel T. Rubio
Abstract: Axillary management in cN + axillary nodes after neoadjuvant systemic therapy (NST) in breast cancer (BC) remains under research with the aim of de-escalation of axillary node dissection (ALND). Several axillary guided localization techniques have been reported. This study evaluates the safety of intraoperative ultrasound (IOUS) guided targeted axillary dissection (TAD) in a large sample after the results of ILINA trial.
Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: meta-analysis
Autores: Eirini Pantiora, Marios Konstantinos Tasoulis, Antonios Valachis, Staffan Eriksson, Thorsten Kühn, Andreas Karakatsanis, Isabel T Rubio
Abstract: Superparamagnetic iron oxide nanoparticles (SPIO) have been used as a tracer for sentinel lymph node (SLN) localization in breast cancer, demonstrating comparable performance to the combination of radioisotope (RI) and blue dye (BD).
Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literatur
Autores: Helle Kristine Skjerven, Even Moa Myklebust, Christian Korvald, Alina Carmen Porojnicu, Rolf Kaaresen, Solveig Hofvind, Ellen Schlicting, Kristine Kleivi Sahlberg
Abstract: For Ductal Carcinoma in Situ (DCIS), recurrence is shown to be higher after skin-sparing (SSM) versus simple (SM) mastectomy. This study aimed to compare the two groups recurrence rates, disease-free survival (DFS), and overall (OS) survival.
Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women
Autores: Helle Kristine Skjerven, Even Moa Myklebust, Christian Korvald, Alina Carmen Porojnicu, Rolf Kaaresen, Solveig Hofvind, Ellen Schlicting, Kristine Kleivi Sahlberg
Abstract: For Ductal Carcinoma in Situ (DCIS), recurrence is shown to be higher after skin-sparing (SSM) versus simple (SM) mastectomy. This study aimed to compare the two groups recurrence rates, disease-free survival (DFS), and overall (OS) survival.
Advances and controversies in management of breast ductal carcinoma in situ (DCIS)
Autores: Gabriel Farante, Antonio Toesca, Francesca Magnoni, Germana Lissidini, José Vila, Mauro Mastropasqua, Giuseppe Viale d e, Silvia Penco, Enrico Cassano, Matteo Lazzeroni, Bernardo Bonanni, Maria Cristina Leonardi, Francisco Ripoll-Orts, Giuseppe Curigliano, Roberto Orecchia, Viviana Galimberti, Paolo Veronesi, L. Fougo
Abstract: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. DCIS is particularly clinically challenging, due to its heterogeneous pathological and biological traits and its management is continually evolving towards more personalized and less aggressive therapies. This article suggests evidence-based guidelines for proper DCIS clinical management, which should be discussed within a multidisciplinary team in order to propose the most suitable approach in clinical practice, taking into account recent scientific studies.. Here we include updated multidisciplinary treatment protocols and techniques in accordance with the most recent contributions published on this topic in the peer-reviewed medical literature, and we outline future perspectives.
The requirements of a specialist breast centre
Autores: Laura Biganzoli, Fatima Cardoso, Marc Beishon, David Cameron, Luigi Cataliotti, Charlotte E. Coles, Roberto C. Delgado Bolton, Maria Die Trill, Sema Erdem, Maria Fjell, Romain Geiss, Mathijs Goossens, Christiane Kuhl, Lorenza Marotti , Peter Naredi, Simon Oberst, Jean Palussiere , Antonio Ponti , Marco Rosselli Del Turco, Isabel T. Rubio, Anna Sapino, Elzbieta Senkus-Konefka, Marko Skelin, Berta Sousa, Tiina Saarto, Alberto Costa, Philip Poortmanso
Abstract: This article is an update of the requirements of a specialist breast centre, produced by EUSOMA and
endorsed by ECCO as part of Essential Requirements for Quality Cancer Care (ERQCC) programme, and
ESMO. To meet aspirations for comprehensive cancer control, healthcare organisations must consider the
requirements in this article, paying particular attention to multidisciplinarity and patient-centred
pathways from diagnosis, to treatment, to survivorship.
Breast cancer patient-reported outcomes on level 1 and level 2 oncoplastic procedures using BREAST-Q®
Autores: C. A. Pinto, B. Peleteiro, C. S. Pinto, F. Osório, S. Costa, A. Magalhães, H. Mora, J. Amaral, D. Gonçalves & . J.L.Fougo
Abstract: In breast cancer management not only mortality and surgical morbidity measurements are important but also patient satisfaction indexes. The authors evaluated the satisfaction and health-related quality of life (HRQOL) using the breast-conserving therapy (BCT) and breast reduction (BR) modules of BREAST-Q®.
Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients
Autores: C. S. Pinto; B. Peleteiro; · C. A. Pinto; F. Osório; S. Costa; A. Magalhães; H. Mora; · J. Amaral; D. Gonçalves; J. L. Fougo
Abstract: Background Targeted axillary dissection (TAD) combines sentinel node biopsy (SNB) with the removal of the previously marked metastatic node. TAD is a promising concept for axillary restaging in node-positive breast cancer patients with pathological complete response (pCR) to neoadjuvant therapy (NAT). We aimed to evaluate TAD feasibility in this context.
Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry
Autores: Antonio J. Esgueva, MD, PhD, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, Martin Espinosa-Bravo, Zolta ́n Ma ́trai, Andrii Zhygulin, Arvids Irmejs, Carlos Mavioso, Francesco Meani, Eduardo Gonzalez, Murat O ̈ zdemir, Tanir Allweis, Karol Rogowski, Catarina Rodrigues dos Santos, Henrique Mora, Riccardo Ponzone, Domenico Samorani, Cornelis van de Velde, Riccardo A. Audisio, Isabel T. Rubio, MD, PhD on behalf of the INSPIRE collaborators group
Abstract: Nipple-sparing mastectomy (NSM) with immediate breast reconstruction (IBR) is increasingly used for both breast cancer (TNSM) and risk reduction (RRNSM). The aim of the study is to report the results of the INSPIRE registry assessing health-related quality of life (HRQoL) comparing baseline and 1-year follow-up, regarding surgical indications and chemotherapy (CT) received.